Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hypnosis vs. CBT: which works better for anxiety and depression?

NCT ID NCT06484400

Symptom relief Sponsor: Istanbul Nisantasi University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two psychological treatments—cognitive behavioral therapy (CBT) and Ericksonian hypnosis—for reducing symptoms of depression and anxiety. 45 adults with symptoms but no formal diagnosis were randomly assigned to CBT, hypnosis, or a no-treatment control group. Researchers measured changes using standard questionnaires to see which approach worked best.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cognitive Behavioral Therapy and Ericksonian Hypnotherapy
What this could lead to
If successful, this could show that Ericksonian hypnosis is as effective as CBT for reducing depression and anxiety symptoms, offering another treatment option.
What could go wrong
This is a small, completed study with only 45 participants, so results may not apply to everyone. It also included people without a formal diagnosis, limiting generalizability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Sep 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: Participants must be between 18 and 65 years old. * Symptoms: Participants must display symptoms of depression and/or anxiety, but not necessarily have a clinical diagnosis. * Voluntary Participation: Participants must voluntarily agree to participate and must be able to provide informed consent. * Residency: Participants must reside in or near the study location (Istanbul) to attend in-person sessions. * Language: Participants must be proficient in the language in which the therapy is delivered (presumably Turkish). * Availability: Participants must be available to attend all scheduled sessions over the course of the study (12 weekly sessions). Exclusion Criteria: * Psychiatric Diagnosis: Individuals with a severe psychiatric disorder requiring immediate or intensive intervention (e.g., schizophrenia, bipolar disorder, or severe depression with suicidal ideation). * Current Psychotherapy: Individuals currently receiving other forms of psychotherapy or psychological treatment. * Substance Abuse: Individuals with active substance abuse issues or dependencies that could interfere with therapy. * Cognitive Impairments: Individuals with cognitive impairments or neurological disorders that would limit their ability to participate fully in therapy. * Medical Conditions: Individuals with severe medical conditions that could interfere with participation in the study or pose a risk during the therapy sessions. * Language Barrier: Non-Turkish speakers or those who do not understand the language well enough to benefit from therapy conducted in Turkish. * Previous Participation: Individuals who have previously participated in similar studies or interventions, to avoid potential biases in responses and outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression, anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder Depression depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression, anxiety

Contacts and locations

Locations

  • Metin Çınaroğlu

    Istanbul, Istanbul, 34277, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.